Wockhardt Limited (WOCKPHARMA)

1,427.75

INR
+71.70(+5.29%)
As of December 2, 2024 10:00:00 AM

Wockhardt Limited Share Price Information

24 hour Low and High

Low: 1352.15
High: 1409.75

All time High

5071.68

Price Change 1h

+₹78.85 +5.85%

Price Change 1d

+₹78.85 +5.85%

Price Change 1w

+₹ +%

Wockhardt Limited Market Information

Exchange

NSE

Market Cap

17712.04 Cr

About Wockhardt Limited Share

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

2386

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Multibagger stock! Wockhardt shares rally 16% to hit new 52-wk high; here's why
  • Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
  • Wockhardt hit the upper circuit on Wednesday while Premier Explosives and Sky Gold hit the lower circuit
  • Private companies invested in Wockhardt Limited (NSE:WOCKPHARMA) copped the brunt of last week's ₹7.8b market cap decline
  • Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control Organization

FAQs

Wockhardt Limited (WOCKPHARMA)

1,427.75

INR
+71.70(+5.29%)
As of December 2, 2024 10:00:00 AM

Wockhardt Limited Share Price Information

24 hour Low and High

Low: 1352.15
High: 1409.75

All time High

5071.68

Price Change 1h

+₹78.85 +5.85%

Price Change 1d

+₹78.85 +5.85%

Price Change 1w

+₹ +%

Wockhardt Limited Market Information

Exchange

NSE

Market Cap

17712.04 Cr

About Wockhardt Limited Share

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

2386

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Multibagger stock! Wockhardt shares rally 16% to hit new 52-wk high; here's why
  • Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
  • Wockhardt hit the upper circuit on Wednesday while Premier Explosives and Sky Gold hit the lower circuit
  • Private companies invested in Wockhardt Limited (NSE:WOCKPHARMA) copped the brunt of last week's ₹7.8b market cap decline
  • Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control Organization

FAQs